Patents Assigned to Merck Patents GmbH
  • Patent number: 10745430
    Abstract: Molybdenum complexes and use thereof in thin film deposition, such as CVD and ALD are provided herein. The molybdenum complexes correspond in structure to Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are independently selected from the group consisting of hydrogen, alkyl, and trialkylsilyl; and at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 is trialkylsilyl.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: August 18, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Shaun Garratt, Paul Williams
  • Patent number: 10745620
    Abstract: The invention relates to a reactive mesogen (RM) formulation comprising a conductive additive, to a polymer film obtained thereof, and the use of the RM formulation and polymer film in optical or electrooptical components or devices, like optical retardation films for liquid crystal displays (LCDs).
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: August 18, 2020
    Assignee: Merck Patent GmbH
    Inventors: Graham Smith, Owain Llyr Parri, Vicki Cook, Georg Bernatz, David Wilkes, Jonathan Henry Wilson, Mark James, Philip Edward May
  • Patent number: 10745616
    Abstract: The present invention relates to alkaline earth aluminate phosphors, to a process for the preparation thereof and to the use thereof as conversion phosphors. The present invention also relates to an emission-converting material comprising at least the conversion phosphor according to the invention, and to the use thereof in light sources, in particular pc-LEDs (phosphor converted light emitting devices). The present invention furthermore relates to light sources, in particular pc-LEDs, and to lighting units which comprise a primary light source and the emission-converting material according to the invention.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: August 18, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Aleksander Zych, Mathias Rapphahn, Ralf Petry, Ingo Koehler, Andreas Benker, Stefan Tews
  • Patent number: 10745399
    Abstract: A compound of formula (IV) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof These imidazolonylquinoline compounds are useful in the inhibition, regulation and/or modulation of signal transduction by kinases, in particular ATM kinase, furthermore in pharmaceutical compositions, and in their use for the treatment of diseases which relate to ATM kinase, in particular cancer.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: August 18, 2020
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Kai Schiemann
  • Publication number: 20200253949
    Abstract: Compounds of the formula I in which X, Q, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Application
    Filed: March 27, 2017
    Publication date: August 13, 2020
    Applicant: Merck Patent GmbH
    Inventor: Hans-Peter BUCHSTALLER
  • Publication number: 20200255740
    Abstract: The invention relates to a liquid crystal mixture characterised in that it comprises one or more photoreactive mesogens of formula I wherein the parameters and groups occurring are defined as indicated in claim 1, to a process for the fabrication of liquid crystal displays using these liquid crystal mixtures and to a liquid crystal display obtainable by this process. The invention further relates to new compounds of formula I.
    Type: Application
    Filed: December 2, 2016
    Publication date: August 13, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Kevin ADLEM, Alex DAVIS, Joseph SARGENT, Ian Charles SAGE, Edward PLUMMER, Izumi SAITO, Rocco FORTTE, Helga HAAS, Lars LIETZAU
  • Publication number: 20200255741
    Abstract: The present application relates to a liquid-crystalline material comprising a sterically hindered N-oxide and a dye. The invention furthermore relates to the use of the liquid-crystalline material in an optical switching device for regulation of the passage of sunlight.
    Type: Application
    Filed: May 16, 2017
    Publication date: August 13, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Michael JUNGE, Ursula PATWAL, Ewa Dominica PTAK
  • Publication number: 20200255739
    Abstract: A light modulation element comprising, preferably consisting of a cholesteric liquid crystalline medium sandwiched between two opposing substrates, an electrode arrangement, which is capable to allow the application of an electric field, which is substantially perpendicular to the main plane of substrate or the layer of the cholesteric liquid-crystalline medium, characterized in that one of the substrates is provided with a processed alignment layer adjacent to the cholesteric liquid crystalline medium and the other substrate is either provided with an unprocessed alignment layer adjacent to the cholesteric liquid crystalline medium or is not provided with an alignment layer. The invention is further related to a method of production of said light modulation element and to the use of said light modulation element in various types of optical and electro-optical devices, such as electro-optical displays, liquid crystal displays (LCDs), non-linear optic (NLO) devices, and optical information storage devices.
    Type: Application
    Filed: May 16, 2017
    Publication date: August 13, 2020
    Applicant: Merck Patent GmbH
    Inventors: Bernd FIEBRANZ, Peter BEST, Meike KRUMWIEDE, Simon SIEMIANOWSKI
  • Publication number: 20200255737
    Abstract: The present invention relates to liquid-crystalline media comprising one or more pleochroic compounds, and one or more compounds selected from the group of compounds of formulae I, II and III, in which the groups have the meanings as set forth in claim 1, and to components comprising these media for high-frequency technology, in particular phase shifters and microwave array antennas.
    Type: Application
    Filed: January 20, 2017
    Publication date: August 13, 2020
    Applicant: Merck Patent GmbH
    Inventors: Michael WITTEK, Dagmar KLASS, Peer KIRSCH
  • Publication number: 20200254098
    Abstract: The present invention relates to the use of spray-dried sorbitol, such as ParteckĀ® SI, as plasticizer for polymer containing compositions processed by (hot) melt extrusion. Due to its improved properties, achieved by its special manufacturing process (spray drying), this direct compressible excipient shows more additional benefits than the same substance in crystalline state.
    Type: Application
    Filed: May 10, 2017
    Publication date: August 13, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter LUBDA, Mengyao ZHENG, Alessandro Giuseppe ELIA, Nicole DI GALLO
  • Publication number: 20200255796
    Abstract: The present invention relates to the use of sulfocysteine and derivatives thereof as cell culture additives to reduce the trisulfide levels in proteins produced in cell culture.
    Type: Application
    Filed: April 25, 2017
    Publication date: August 13, 2020
    Applicant: Merck Patent GmbH
    Inventor: Aline ZIMMER
  • Publication number: 20200255736
    Abstract: The invention relates to a polymerisable LC material comprising at least one di- or multireactive mesogenic compound and at least one compound of formula CO-1, wherein L31, L32, A31, and R31 have one of the meanings as given in claim 1. Furthermore, the present invention relates also to a method for its preparation, a polymer film with improved thermal durability obtainable from the corresponding polymerisable LC material, to a method of preparation of such polymer film, and to the use of such polymer film and said polymerisable LC material for optical, electro-optical, decorative or security devices.
    Type: Application
    Filed: May 15, 2017
    Publication date: August 13, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Stephen MULCAHY, Iain GARDINER
  • Patent number: 10738243
    Abstract: The present invention relates to dielectrically positive liquid-crystalline media comprising one or more compounds of the formula I, and one or more compounds selected from the group of the compounds of the formulae II and III and/or IV, in which the parameters have the respective meanings indicated in the specification, and optionally one or more further dielectrically positive compounds and optionally one or more further dielectrically neutral compounds, and to liquid-crystal displays, especially active-matrix displays and in particular TN, IPS and FFS displays, containing these media.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: August 11, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Michael Junge, Volker Reiffenrath, Elvira Montenegro, Michael Wittek, Markus Czanta
  • Patent number: 10738120
    Abstract: The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: August 11, 2020
    Assignees: Merck Patent GmbH, Pfizer Inc.
    Inventors: Claudia Wilm, Klaus Schneider, Heike Dahmen
  • Patent number: 10741778
    Abstract: An electronic component (10) comprising a plurality of switching elements (1) which comprise, in this sequence, a first electrode (16), a molecular layer (18) bonded to a substrate, and a second electrode (20), where the molecular layer essentially consists of molecules (M) which contain a connecting group (V) and an end group (E) having a polar or ionic function, is suitable as memristive device for digital information storage.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: August 11, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Peer Kirsch, Qiong Tong, Andreas Ruhl, Marc Tornow, Achyut Bora
  • Patent number: 10738240
    Abstract: The present invention relates to thiadiazoloquinoxaline derivatives of the formula I, in which R11, R12, A11, A12, A21, A22, Z11, Z12, Z21, Z22, W, X11, X12, r and s have the meanings indicated in Claim 1, to processes and intermediates for the preparation thereof, to the use of the compounds of the formula I for optical, electro-optical and electronic purposes, in particular in liquid-crystal media and in devices for regulating the passage of energy from an outside space into an inside space, and to these LC media and the devices comprising these media.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: August 11, 2020
    Assignee: Merck Patent GmbH
    Inventors: Peer Kirsch, Andreas Ruhl, Susann Gunst, Michael Junge, Ursula Patwal, Mila Fischer
  • Publication number: 20200248078
    Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal media comprising them, and to the use of the polymerizable compounds and liquid crystalline media for optical, electro-optical and electronic purposes, in particular in liquid crystalline displays, especially in liquid crystalline displays of the polymer sustained alignment type.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 6, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Qiong TONG, Nico SCHWEBEL, Constanze BROCKE, Kaja Christina DEING, Julian VOGT, Elisabeth MEYER
  • Publication number: 20200248077
    Abstract: The invention relates to a medium comprising at least 60% of one or more compounds of formula I wherein R11, R12, MG11, MG12 and Sp1 have the meaning given herein below, to the use of such media in liquid crystal devices, in particular in flexoelectric liquid crystal devices, and to a flexoelectric liquid crystal device comprising a liquid crystal medium according to the present invention.
    Type: Application
    Filed: November 18, 2016
    Publication date: August 6, 2020
    Applicant: Merck Patent GmbH
    Inventors: Simon SIEMIANOWSKI, Konstantin SCHNEIDER
  • Publication number: 20200246270
    Abstract: The present invention relates to novel pharmaceutical formulations which have controlled, delayed release of active ingredient, and to a process for the preparation of such formulations. The invention additionally relates to the use of these novel pharmaceutical administration forms as medicaments for the treatment of diseases which require delayed release of the active ingredient, such as hypertension, or asthmatic diseases.
    Type: Application
    Filed: April 21, 2020
    Publication date: August 6, 2020
    Applicant: Merck Patent GmbH
    Inventors: Finn BAUER, Thorsten WEDEL, Guenter MODDELMOG, Gudrun BIRK, Roberto OGNIBENE, Dieter LUBDA
  • Publication number: 20200247916
    Abstract: The present invention relates to the use of hydrophilic compounds of the formula I as photopolymerisation initiators of polymerisable substance mixtures which comprise unsaturated compounds, or for the photochemical crosslinking of linear polymers, in which the parameters have the meaning indicated in Claim 1, to sealants for liquid-crystal displays which comprise the hydrophilic photoinitiators, to novel hydrophilic photoinitiators of the formula I, and to the liquid-crystal displays produced using these sealants.
    Type: Application
    Filed: October 5, 2016
    Publication date: August 6, 2020
    Applicant: Merck Patent GmbH
    Inventors: Peer KIRSCH, Qiong TONG, Alexander HAHN, Leo WEEGELS, Steffen GNAUCK, Sven SCHUEPFER, Peter LEONHARD, Claudia ENDERS